Rain Oncology to Report Fourth Quarter and Full Year 2022 Financial Results and Highlights of Recent Progress on March 9, 2023
NEWARK, Calif., Thursday, February23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of theMDM2-p53 complex that reactivates p53, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 and highlights of recent progress on Thursday, March 9, 2023.On that day, management will host a conference call and webcast at 2:00 pm PT(5:00 pm ET) to discuss the Company’s business and financial results.
Conference Call and Webcast Details:
Date: March9, 2023
Time: 2:00 PT (5:00 pm ET)
Dial In Numbers: 1 (877) 704-4453 (U.S. Toll Free) / 1 (201) 389-0920(International)
Conference ID: 13735982
Webcast Link: https://edge.media-server.com/mmc/p/pdg97w5e
Replay of the call will be available by visiting the "Events" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.
About Rain Oncology Inc.
Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
InvestorContact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com
